Fluor Corporation has been selected by a leading biologics company to perform procurement and construction management for a large-scale biologics drug substance manufacturing facility located in

Scandinavia.

 

The company will book the multi-hundred-million-dollar reimbursable contract value in the third quarter of 2022, a statement by the company said.

 

The project is being led by Fluor’s Advanced Technologies & Life Sciences business including support from its Nordic Technology Hub in Copenhagen, Denmark.

 

The facility will produce new capacity for advanced biologics that are used in a variety of treatments including vaccines, oncology and quality-of-life medicines, it said.

 

Fluor has performed the planning and enabling work for this project, and construction is now underway with the facility scheduled to be operational by 2025.--TradeArabia News Service